Chronicle Journal: Finance

Roche to buy gene therapy specialist Spark in $4.3 billion deal

Roche on Monday said it will buy Spark Therapeutics in a transaction valued at $4.3 billion as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.